REAL-WORLD STUDY OF METASTATIC MERKEL CELL CARCINOMA PATIENTS RECEIVING CHECKPOINT INHIBITORS (CPIS) VS. CHEMOTHERAPY TREATMENTS

被引：0
|
作者：
Zheng, Y. [1 ]
Kim, R. [2 ]
Yu, T. [1 ]
Dreyfus, J. [3 ]
Gayle, J. A. [3 ]
Wassel, C. L. [3 ]
Phatak, H. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Premier Inc, Charlotte, NC USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN317
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [31] Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy
    Schwartzberg, Lee
    Korytowsky, Beata
    Penrod, John R.
    Zhang, Ying
    Le, T. Kim
    Batenchuk, Cory
    Krug, Lee
    CLINICAL LUNG CANCER, 2019, 20 (04) : 287 - +
  • [32] Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
    Hanna, Glenn J.
    Ruiz, Emily S.
    LeBoeuf, Nicole R.
    Thakuria, Manisha
    Schmults, Chrysalyne D.
    Decaprio, James A.
    Silk, Ann W.
    BRITISH JOURNAL OF CANCER, 2020, 123 (10) : 1535 - 1542
  • [33] Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma
    McLean, Luke S.
    Lim, Annette M.
    Bressel, Mathias
    Thai, Alesha A.
    Rischin, Danny
    DRUGS & AGING, 2024, 41 (03) : 271 - 281
  • [34] Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI)
    Glenn J. Hanna
    Emily S. Ruiz
    Nicole R. LeBoeuf
    Manisha Thakuria
    Chrysalyne D. Schmults
    James A. Decaprio
    Ann W. Silk
    British Journal of Cancer, 2020, 123 : 1535 - 1542
  • [35] Real-world experience of immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: a Korean multicenter study
    Lee, Kyunglim
    Chung, Young Eun
    Noh, Joseph
    Kim, Se Ik
    Lee, Jung-Yun
    Lee, Yong Jae
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A233 - A233
  • [36] Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
    Manako, Tomomi
    Yasumatsu, Ryuji
    Nakano, Takafumi
    Matsuo, Mioko
    Takeuchi, Toranishin
    Taura, Masahiko
    Tamae, Akihiro
    Yamauchi, Moriyasu
    Masuda, Muneyuki
    Taguchi, Kenichi
    Nakagawa, Takashi
    IN VIVO, 2023, 37 (02): : 747 - 755
  • [37] Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
    Zaremba, Anne
    Chorti, Eleftheria
    Jockenhoefer, Finja
    Bolz, Saskia
    Sirin, Selma
    Glas, Martin
    Becker, Juergen C.
    Ugurel, Selma
    Boesch, Alexander
    Schadendorf, Dirk
    Livingstone, Elisabeth
    Hagenacker, Tim
    Zimmer, Lisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
    Stege, H. M.
    Haist, M.
    Schultheis, S.
    Fleischer, M. I.
    Mohr, P.
    Ugurel, S.
    Terheyden, P.
    Thiem, A.
    Kiecker, F.
    Leiter, U.
    Becker, J. C.
    Meissner, M.
    Kleeman, J.
    Pfoehler, C.
    Hassel, J.
    Grabbe, S.
    Loquai, C.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3313 - 3322
  • [39] Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma - a retrospective multicenter retrospective study
    Stege, H.
    Haist, M.
    Mohr, P.
    Ugurel, S.
    Terheyden, P.
    Thiem, A.
    Kiecker, F.
    Leiter-Stoeppke, U.
    Becker, J. C.
    Meissner, M.
    Kleemann, J.
    Wenk, S.
    Pfoehler, C.
    Hassel, J. C.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 12 - 13
  • [40] Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
    H. M. Stege
    M. Haist
    S. Schultheis
    M. I. Fleischer
    P. Mohr
    S. Ugurel
    P. Terheyden
    A. Thiem
    F. Kiecker
    U. Leiter
    J. C. Becker
    M. Meissner
    J. Kleeman
    C. Pföhler
    J. Hassel
    S. Grabbe
    C. Loquai
    Cancer Immunology, Immunotherapy, 2021, 70 : 3313 - 3322
12345